Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 4
2022 4
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Cardiovascular risk factors among people with drug-resistant tuberculosis in Uganda.
Baluku JB, Nabwana M, Nalunjogi J, Muttamba W, Mubangizi I, Nakiyingi L, Ssengooba W, Olum R, Bongomin F, Andia-Biraro I, Worodria W. Baluku JB, et al. Among authors: nalunjogi j. BMC Cardiovasc Disord. 2022 Nov 4;22(1):464. doi: 10.1186/s12872-022-02889-y. BMC Cardiovasc Disord. 2022. PMID: 36333654 Free PMC article.
Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study.
Nalunjogi J, Mucching-Toscano S, Sibomana JP, Centis R, D'Ambrosio L, Alffenaar JW, Denholm J, Blanc FX, Borisov S, Danila E, Duarte R, García-García JM, Goletti D, Ong CWM, Rendon A, Thomas TA, Tiberi S, van den Boom M, Sotgiu G, Migliori GB; Global Tuberculosis Network. Nalunjogi J, et al. Int J Infect Dis. 2023 May;130 Suppl 1:S25-S29. doi: 10.1016/j.ijid.2023.02.025. Epub 2023 Mar 8. Int J Infect Dis. 2023. PMID: 36893943 Free PMC article.
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda.
Ssengooba W, Komakech K, Namiiro S, Byabajungu H, Nalunjogi J, Katagira W, Kimuli I, Joloba ML, Adakun S, Nakiyingi L, Torrea G, Kirenga BJ. Ssengooba W, et al. Among authors: nalunjogi j. J Clin Tuberc Other Mycobact Dis. 2021 Nov 6;25:100286. doi: 10.1016/j.jctube.2021.100286. eCollection 2021 Dec. J Clin Tuberc Other Mycobact Dis. 2021. PMID: 34816021 Free PMC article.
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
Rosu L, Madan JJ, Tomeny EM, Muniyandi M, Nidoi J, Girma M, Vilc V, Bindroo P, Dhandhukiya R, Bayissa AK, Meressa D, Narendran G, Solanki R, Bhatnagar AK, Tudor E, Kirenga B, Meredith SK, Nunn AJ, Bronson G, Rusen ID, Squire SB, Worrall E; STREAM Study Health Economic Evaluation Collaborators. Rosu L, et al. Lancet Glob Health. 2023 Feb;11(2):e265-e277. doi: 10.1016/S2214-109X(22)00498-3. Epub 2022 Dec 21. Lancet Glob Health. 2023. PMID: 36565704 Free article. Clinical Trial.
13 results